[Bronchoscopy in the post-therapeutic monitoring of patients with bronchial carcinoma].

Plucne Bolesti

Klinika za plućne bolesti Jordanovac, Zagreb.

Published: September 1991

A study of 970 patients treated for bronchogenic carcinoma (operation, cytostatic therapy, irradiation) reveal that only 122 (12.5%) were evaluated by the bronchoscopy. Among 47 (38.5%) out of 122 patients recidivation was confirmed (cytology or histology). The efficacy of radiology and sputum cytology is poor. Only 22/47 (47%) had radiologic evidence of recidivation and 18/47 (38%) had positive sputum cytology. Radiology and sputum cytology reveal recidivation in 27/47 (57%) patients. It means that bronchoscopy is the method of choice in the posttherapeutic monitoring of patients with bronchogenic carcinoma.

Download full-text PDF

Source

Publication Analysis

Top Keywords

sputum cytology
12
monitoring patients
8
bronchogenic carcinoma
8
radiology sputum
8
patients
5
[bronchoscopy post-therapeutic
4
post-therapeutic monitoring
4
patients bronchial
4
bronchial carcinoma]
4
carcinoma] study
4

Similar Publications

Background: Sepsis, a critical global health challenge, accounted for approximately 20% of worldwide deaths in 2017. Although the Sequential Organ Failure Assessment (SOFA) score standardizes the diagnosis of organ dysfunction, early sepsis detection remains challenging due to its insidious symptoms. Current diagnostic methods, including clinical assessments and laboratory tests, frequently lack the speed and specificity needed for timely intervention, particularly in vulnerable populations such as older adults, intensive care unit (ICU) patients, and those with compromised immune systems.

View Article and Find Full Text PDF

Primary bronchial leiomyosarcoma: a diagnostic challenge.

BMC Pulm Med

January 2025

Department of Pathology, Affiliated Hospital of Zunyi Medical University, Zunyi City, Guizhou Province, P.R. China.

Background: Pulmonary bronchial leiomyosarcoma is an extremely rare malignant tumour of the lung originating from the mesenchymal tissue. The retroperitoneal region is the most common site of leiomyosarcoma. It exhibits a high degree of malignancy and a poor prognosis, thereby highlighting the significance of early diagnosis of this disease.

View Article and Find Full Text PDF

Robotic bronchoscopy: Evolution of advanced diagnostic technologies for pulmonary lesions.

Best Pract Res Clin Anaesthesiol

March 2024

1400 Holcombe Blvd, FC 13.2000, Houston, TX, 77030, USA. Electronic address:

Lung cancer is among one of the most commonly diagnosed malignancies and is the leading cause of cancer-related mortality in both men and women globally, with an estimated 1.8 million deaths annually. Moreover, it is also the leading cause of cancer related deaths in the United States (U.

View Article and Find Full Text PDF

BACKGROUNDExisting TB diagnostic tests rely on sputum samples, which can be difficult to collect from all patients. This study examines plasma cell-free DNA (Mtb cfDNA) based quantitative PCR (qPCR) assay for the diagnosis of pulmonary TB (PTB).METHODSThe qPCR assay targeted insertion sequence (IS), and R genes on plasma samples from 106 PTB patients and 60 controls.

View Article and Find Full Text PDF

Using Fourier Transform Infrared spectroscopy (FTIR), it is possible to show chemical composition of materials and / or profile chemical changes occurring in tissues, cells, and body fluids during onset and progression of diseases. For diagnostic application, the use of blood would be the most appropriate in biospectroscopy studies since, (i) it is easily accessible and, (ii) enables frequent analyses of biochemical changes occurring in pathological states. At present, different studies have investigated potential of serum, plasma and sputum being alternative biofluids for lung cancer detection using FTIR.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!